Patients
| Country | Value | Year |
|---|---|---|
| Belgium | 5.9 | 2024 |
| Denmark | 6.4 | 2024 |
| France | 6.5 | 2024 |
| Germany | 7.8 | 2024 |
| Italy | 7.7 | 2024 |
| Netherlands | 5.0 | 2024 |
| Poland | 8.1 | 2024 |
| Russia | 5.9 | 2024 |
| Spain | 9.7 | 2024 |
| Sweden | 5.8 | 2024 |
| Switzerland | 5.3 | 2024 |
| Turkey | 16.5 | 2024 |
| UK | 7.4 | 2024 |
Updated
Reviewed by Chandani Patel
Europe Insulin Pens Market Industry Trends and Forecast to 2034: Segmented by (Type, Needle, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$567.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $645.5 Mn | — | — |
| 2025 (base) | $690.0 Mn | +$44.5 Mn | — |
| 2026 (forecast) | $737.6 Mn | +$47.6 Mn | +6.9% |
| 2027 (forecast) | $788.5 Mn | +$50.9 Mn | +14.3% |
| 2028 (forecast) | $842.9 Mn | +$54.4 Mn | +22.2% |
| 2029 (forecast) | $901.1 Mn | +$58.2 Mn | +30.6% |
| 2030 (forecast) | $963.2 Mn | +$62.2 Mn | +39.6% |
| 2031 (forecast) | $1.03 Bn | +$66.5 Mn | +49.2% |
| 2032 (forecast) | $1.10 Bn | +$71.0 Mn | +59.5% |
| 2033 (forecast) | $1.18 Bn | +$76.0 Mn | +70.5% |
| 2034 (forecast) | $1.26 Bn | +$81.2 Mn | +82.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $690.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.26 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 6.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type and needle (see all) |
| Key players | Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Ypsomed, Owen Mumford and 1 more (see all) |
| Regulator in Europe | EU MDRSource: European Commission, medical devices. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Insulin pens are handheld injectors that give set doses of insulin, as a simpler option than vials and syringes.
Key segments of the insulin pens market include type (Prefilled Pens, Reusable Pens and Connected Pens) and needle (Standard Needles and Safety Needles).
Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the insulin pens market.
Connected devices, lower-priced sensors and new insulins and pills give the insulin pens market room to grow.
High costs for people without cover, price competition and uneven access to care in low-income countries hold back the insulin pens market.
The insulin pens market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.[1] In the countries we cover here, medical devices are regulated by ANSM (France)[2], BfArM (Germany)[3], Ministry of Health (Italy)[4], Roszdravnadzor (Russia)[5], AEMPS (Spain)[6], MHRA (UK)[7], IGJ (Netherlands)[8], FAMHP (Belgium)[9], Swissmedic (Switzerland)[10], Läkemedelsverket (Sweden)[11], Danish Medicines Agency (Denmark)[12], URPL (Poland)[13] and TITCK (Turkey)[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[15]
[1] European Commission, medical devices. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Ministry of Health. Checked 14 Nov 2026.
[5] Roszdravnadzor. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] Health and Youth Care Inspectorate (IGJ). Checked 19 Nov 2026.
[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.
[10] Swissmedic. Checked 19 Nov 2026.
[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.
[12] Danish Medicines Agency. Checked 19 Nov 2026.
[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.
[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.
[15] European Commission, health technology assessment. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how insulin pens products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.
What doctors and scientists are doing in Insulin Pens right now, from free public sources.
| Country | Value | Year |
|---|---|---|
| Belgium | 5.9 | 2024 |
| Denmark | 6.4 | 2024 |
| France | 6.5 | 2024 |
| Germany | 7.8 | 2024 |
| Italy | 7.7 | 2024 |
| Netherlands | 5.0 | 2024 |
| Poland | 8.1 | 2024 |
| Russia | 5.9 | 2024 |
| Spain | 9.7 | 2024 |
| Sweden | 5.8 | 2024 |
| Switzerland | 5.3 | 2024 |
| Turkey | 16.5 | 2024 |
| UK | 7.4 | 2024 |
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe
Europe
Europe
Europe
Europe
Europe
Pharmaceuticals · Europe
Healthcare Services · Europe
Digital Health · Europe
Pharmaceuticals · Europe
Pharmaceuticals · Europe
Pharmaceuticals · Europe